Behcet's syndrome: Bechet disease (BD) is a chronic, relapsing, multisystemic vasculitis characterized by mucocutaneous lesions, as well as articular, vascular, ocular and central nervous system manifestations.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
110 |
4. Check minimum number of eventsNone |
110 |
5. Include endpointsNone |
110 |
6. Filter based on genotype QC (FinnGen only) |
106 |
Control definitions (FinnGen only)
- Control exclude
- M13_SYSTCONNECT
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M35
- Name in latin
- Morbus Behçet
Similar endpoints
↥List of similar endpoints to
Behçet disease
based on the number of shared cases.
Similar with more cases:
- Other systemic involvement of connective tissue (FG)
- Other systemic involvement of connective tissue
- Systemic connective tissue disorders
- Finngen Rheumatological endpoints
- Autoimmune diseases
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 612 | 415 | 187 |
| Only index persons | 535 | 378 | 157 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 53.29 | 53.02 | 54.96 |
| Only index persons | 51.23 | 50.44 | 53.11 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 106 | 82 | 24 |
| Unadjusted period prevalence (%) | 0.02 | 0.03 | 0.01 |
| Median age at first event (years) | 48.45 | 46.69 | 54.44 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 110
- Matched controls
- 1100
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M35.2
ICD-10 Finland
Behçet disease
+∞
143.3
104
*
L04AX01
ATC
azathioprine; systemic
71.2
80.0
46
11
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
18.7
51.8
53
52
L04AX03
ATC
methotrexate; systemic
14.2
39.3
45
51
H02AB06
ATC
prednisolone; systemic
10.7
25.2
92
355
H02AB07
ATC
prednisone; oral
7.7
21.0
37
68
K12.00
ICD-10 Finland
Recurrent oral aphthae
50.4
20.5
24
6
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
5.7
18.7
68
242
N77.8*M35.2
ICD-10 Finland
Ulceration of vulva in Behçet's disease
+∞
18.2
17
*
M35.3
ICD-10 Finland
Polymyalgia rheumatica
60.4
17.7
20
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
8.7
17.3
25
36
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
14.4
15.3
26
23
M05BA04
ATC
alendronic acid; oral
7.2
13.7
23
39
P01BA02
ATC
hydroxychloroquine; oral
6.9
13.6
24
43
R50.9
ICD-10 Finland
Fever, unspecified
5.0
13.1
36
97
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.7
11.9
26
57
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
133.4
11.7
12
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.0
11.5
66
302
Z01.8
ICD-10 Finland
Other specified special examinations
4.3
11.4
39
124
UJF30
NOMESCO Finland
Ileoscopy through colon
5.7
11.3
24
51
Z2446
NOMESCO Finland
Social worker
6.6
11.2
20
36
N76.6
ICD-10 Finland
Ulceration of vulva
66.6
10.9
12
*
L01BA01
ATC
methotrexate; systemic
12.3
9.7
17
16
L04AD01
ATC
ciclosporin; systemic
33.3
9.6
12
*
K12.10
ICD-10 Finland
Stomatitis NOS
109.0
9.6
10
*
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
+∞
9.5
9
*
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
+∞
9.5
9
*
A07EC01
ATC
sulfasalazine; oral, rectal
5.8
9.5
19
38
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
5.7
9.2
19
39
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
5.3
8.5
19
42
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.3
8.2
44
184
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
4.8
8.2
21
52
L04AA01
ATC
[U] ciclosporin
36.3
8.2
10
*
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
7.4
8.2
19
30
M05BA07
ATC
risedronic acid; oral
14.5
8.1
13
10
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
8.5
8.0
17
23
H20.1
ICD-10 Finland
Chronic iridocyclitis
48.6
7.8
9
*
M13.9
ICD-10 Finland
Arthritis, unspecified
6.7
7.6
19
33
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
17.3
7.4
11
7
M35.1
ICD-10 Finland
Other overlap syndromes
+∞
7.4
7
*
N02AX02
ATC
tramadol; systemic, rectal
3.0
7.3
61
325
L04AA06
ATC
mycophenolic acid; systemic
32.4
7.3
9
*
XKD00
NOMESCO Finland
Uroflowmetry
4.6
7.2
19
48
Z3229
NOMESCO Finland
Other healthcare associate professional
6.5
7.1
18
32
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
4.8
7.0
17
40
ZX120
NOMESCO Finland
Intravenous
4.2
7.0
21
59
UJF92
NOMESCO Finland
Capsular endoscopy
24.3
6.8
9
*
L88
ICPC
Rheumatoid/seropositive arthritis
8.3
6.7
14
19
J01FF01
ATC
clindamycin; systemic
2.9
6.5
42
192
M35.7
ICD-10 Finland
Hypermobility syndrome
74.0
6.5
7
*
SBA00
NOMESCO Finland
Microbiological examinations
19.4
6.4
9
5
377
Kela drug reimbursment
Apremilast and dimethyl fumarate (psoriasis)
+∞
6.3
6
*
L04AA32
ATC
apremilast; oral
+∞
6.3
6
*
H04.10
ICD-10 Finland
Dry eye syndrome
3.6
6.2
23
75
UGC12
NOMESCO Finland
Flexible bronchoscopy
6.5
6.1
15
26
Z3231
NOMESCO Finland
Registered nurse
2.8
6.0
40
185
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
19
11
20.54
13.06
1.3
1.4
—
—
—
0
0
15
5
34.32
12.00
1.4
1.4
—
—
—
0
0
15
5
34.32
12.00
1.4
1.4
—
—
—
0
0
15
6
28.60
11.48
1.4
1.3
—
—
—
0
0
15
6
28.60
11.48
1.4
1.3
—
—
—
0
0
15
6
28.60
11.48
1.4
1.3
—
—
—
0
0
32
100
4.10
9.40
1.8
1.8
2.54
2.45
g/l
0.37
27
88
17
19
10.36
8.92
1.5
1.4
—
—
—
0
0
17
20
9.83
8.69
2.3
1.5
—
—
—
0
0
62
314
3.23
8.45
5.1
4.0
35.55
36.22
g/l
0.43
57
299
65
344
3.17
8.11
3.2
2.1
79.52
75.60
nmol/l
0.47
58
311
68
374
3.14
7.85
12.9
7.5
1.23
1.22
mmol/l
0.21
57
318
14
16
9.84
7.30
3.6
2.4
—
—
—
0
0
19
49
4.48
7.05
2.7
1.4
—
—
—
0
0
10
6
18.13
6.88
3.6
1.7
908.70
583.33
e6/l
—
10
6
17
42
4.60
6.63
2.3
1.4
—
—
—
0
0
54
283
2.78
6.47
5.3
2.6
—
—
—
0
0
12
14
9.46
6.24
1.2
1.2
—
—
—
0
0
11
12
10.03
5.94
3.4
2.0
74.36
271.06
ug/l
1.28
11
12
10
11
9.86
5.41
1.1
1.0
—
—
—
0
0
10
11
9.86
5.41
1.2
1.4
—
—
—
0
0
12
19
6.95
5.24
1.8
1.2
—
—
—
0
0
10
12
9.03
5.18
1.2
1.2
—
—
—
0
0
8
7
12.19
4.86
1.3
1.3
—
—
—
0
0
10
14
7.73
4.77
1.4
1.1
—
—
—
0
0
14
32
4.86
4.63
2.5
1.4
—
—
—
0
0
56
337
2.35
4.62
15.7
12.3
1.20
1.18
inr
0.04
12
108
40
208
2.45
4.57
2.7
3.1
533.17
970.66
ng/l
0.98
30
170
13
29
4.94
4.41
1.2
1.4
—
—
—
0
0
7
6
12.33
4.33
1.0
1.3
—
—
—
0
0
28
126
2.64
4.29
4.0
1.6
—
—
—
0
0
36
185
2.41
4.18
2.9
1.9
3.05
2.94
mg/l
0.09
31
160
37
197
2.32
3.94
3.1
2.9
315.72
4311.83
umol/l
0.80
32
167
6
5
12.58
3.81
1.0
1.2
—
—
—
0
0
6
5
12.58
3.81
1.0
1.4
—
—
—
0
0
6
5
12.58
3.81
1.0
1.4
—
—
—
0
0
12
30
4.36
3.73
1.4
1.3
—
—
—
0
0
63
424
2.14
3.70
8.4
4.4
0.00
0.00
estimate
-0.00
13
84
30
151
2.36
3.59
1.4
1.2
11.61
37.24
iu/ml
—
7
50
63
427
2.11
3.59
6.3
3.2
0.00
0.00
estimate
-0.00
13
83
9
17
5.66
3.59
2.1
3.2
3.98
3.88
g/l
—
9
17
38
212
2.21
3.58
1.7
1.3
0.59
1.73
u/ml
—
10
53
10
22
4.89
3.52
1.1
1.5
413.80
241.92
ug/g
—
5
12
62
424
2.06
3.39
6.3
3.1
0.00
0.00
estimate
-0.00
13
88
25
123
2.34
3.13
3.9
2.2
1.77
3.66
e6/l
0.73
18
57
8
16
5.30
3.11
1.0
1.1
—
—
—
0
0
9
21
4.57
3.07
1.7
1.4
—
—
—
0
0
9
22
4.36
2.95
1.7
1.1
—
—
—
0
0
6
9
6.97
2.90
1.0
1.2
—
—
—
0
0
6
9
6.97
2.90
7.8
2.2
—
—
—
0
0
6
9
6.97
2.90
7.8
2.2
—
—
—
0
0
19
85
2.49
2.90
2.8
1.5
—
—
—
0
0
18
79
2.53
2.86
16.0
7.7
104.56
103.95
mmol/l
0.20
18
79
8
18
4.70
2.85
2.1
4.1
0.00
0.00
g/l
—
8
18
8
18
4.70
2.85
2.1
4.1
0.00
0.00
g/l
—
8
18
5
6
8.65
2.77
1.0
1.3
—
—
—
0
0
5
6
8.65
2.77
1.6
2.0
—
—
—
0
0
5
6
8.65
2.77
1.8
1.0
—
—
—
0
0
24
122
2.24
2.77
2.7
3.2
473.80
128.20
ng/l
0.32
15
90
20
94
2.38
2.75
7.4
7.1
—
—
—
0
0
8
19
4.45
2.73
2.1
4.1
0.00
0.00
g/l
—
8
19
18
82
2.43
2.65
2.9
1.8
1413.00
28.44
u/l
0.47
13
66
9
25
3.82
2.64
2.9
2.3
95.11
93.72
%
—
9
25
8
20
4.23
2.62
1.6
1.4
—
—
—
0
0
8
20
4.23
2.62
1.6
1.4
—
—
—
0
0
33
195
1.99
2.58
2.5
1.7
1.20
0.87
mg/l
0.21
25
148
6
11
5.70
2.58
2.2
1.9
—
—
—
0
0
6
11
5.70
2.58
1.2
1.2
—
—
—
0
0
42
270
1.90
2.57
3.0
3.3
2.33
2.35
mmol/l
0.55
36
245
5
7
7.41
2.57
1.8
1.1
—
—
—
0
0
7
16
4.59
2.52
1.6
1.3
—
—
—
0
0
18
84
2.37
2.51
2.9
1.6
—
—
—
0
0
8
23
3.67
2.32
2.1
3.5
—
—
—
0
0
10
35
3.04
2.27
2.2
2.5
0.68
0.74
%
—
10
35
5
9
5.76
2.23
2.0
2.2
—
—
—
0
0
61
457
1.75
2.17
9.8
6.0
9.18
9.87
umol/l
0.71
56
430
46
318
1.77
2.17
4.4
3.5
24.96
53.70
ng/l
0.83
27
196
19
98
2.13
2.11
1.6
2.1
4.15
5.97
umol/l
0.76
13
80
5
10
5.18
2.09
1.2
1.2
—
—
—
0
0
13
57
2.45
2.07
2.5
4.8
4.14
4.48
pmol/l
0.61
13
51
44
306
1.73
2.00
2.2
1.8
106.17
98.27
pmol/l
0.52
30
151
38
254
1.76
1.98
2.6
2.7
51.91
56.62
u/l
0.55
33
230
6
16
3.90
1.96
7.8
1.8
—
—
—
0
0
6
16
3.90
1.96
8.3
1.8
—
—
—
0
0
6
16
3.90
1.96
1.3
1.1
—
0.80
—
0
7
5
11
4.70
1.96
2.2
2.1
—
—
—
0
0
99
877
2.29
1.87
28.4
13.7
139.51
139.79
mmol/l
0.47
94
851
5
12
4.31
1.84
1.0
1.4
—
—
—
0
0
24
142
1.88
1.84
3.5
2.0
0.42
0.89
e6/l
1.16
18
75
100
895
2.29
1.75
33.9
11.5
14.16
22.43
mg/l
3.25
91
672
13
62
2.24
1.73
5.0
2.9
2.41
2.75
mmol/l
0.14
13
50
6
19
3.28
1.68
6.0
2.6
58.00
56.74
%
—
6
19
10
44
2.40
1.60
2.4
3.1
126.00
129.77
g/l
—
10
44
9
38
2.49
1.49
2.3
2.5
1.33
1.28
%
—
9
38
9
38
2.49
1.49
27.1
5.0
26.06
26.16
mmol/l
—
9
38
7
28
2.60
1.48
1.3
1.1
—
—
—
0
0
7
28
2.60
1.48
1.3
1.1
—
—
—
0
0
31
211
1.65
1.47
2.2
1.6
—
—
—
0
0
23
144
1.76
1.47
1.9
1.7
831.94
1181.96
nmol/l
1.07
17
108
15
82
1.96
1.44
1.7
1.8
—
—
—
0
0
53
416
1.53
1.37
2.9
2.6
—
—
—
0
0
44
332
1.54
1.36
6.3
3.2
—
—
—
0
0
30
207
1.62
1.35
3.4
2.2
—
—
—
0
0
8
35
2.38
1.30
7.0
1.7
—
—
—
0
0
23
152
1.65
1.22
1.4
1.3
40.30
9.09
u/ml
—
6
65
10
50
2.10
1.20
1.0
1.0
—
—
—
0
0
8
39
2.13
1.18
1.3
1.4
—
—
—
0
0
12
66
1.92
1.14
1.6
1.8
—
—
—
0
0
7
31
2.34
1.12
2.1
1.5
—
—
—
0
0
32
234
1.52
1.11
7.8
3.4
0.00
0.00
estimate
-0.00
13
83
14
82
1.81
1.11
3.2
3.2
—
—
—
0
0
91
828
1.57
0.98
23.6
10.7
86.70
85.97
ml/min/173m2
0.11
85
666
10
55
1.90
0.95
1.4
1.2
—
—
—
0
0
8
42
1.97
0.91
2.5
1.5
—
—
—
0
0
25
188
1.43
0.75
1.5
1.4
—
—
—
0
0
15
101
1.56
0.75
4.4
3.7
28.22
32.26
%
—
9
70
12
77
1.63
0.72
1.4
4.4
2.40
7.68
ug/l
—
5
61
7
42
1.71
0.70
32.3
11.5
1.14
1.48
%
—
7
42
7
42
1.71
0.70
32.3
11.5
0.43
0.69
%
—
7
42
80
850
0.78
0.47
4.4
4.0
4.79
4.71
mmol/l
0.27
75
800
82
863
0.80
0.39
4.6
4.5
2.69
2.79
mmol/l
0.49
77
808
5
36
1.41
0.38
1.2
1.3
—
274.51
—
0
20
74
785
0.82
0.37
5.8
5.1
38.25
39.16
mmol/mol
0.38
74
743
68
641
1.16
0.27
4.3
3.4
—
—
—
0
0
5
38
1.33
0.23
2.0
3.0
25.88
24.47
mmol/l
—
5
38
5
39
1.30
0.23
2.2
3.3
41.32
42.93
%
—
5
39
5
42
1.20
0.22
1.4
1.6
—
—
—
0
0
101
990
1.25
0.21
45.3
18.0
40.31
40.30
%
0.01
95
941
6
49
1.24
0.20
2.5
1.5
305.83
286.25
mu/l
—
6
44
14
120
1.19
0.17
1.3
1.7
1.32
1.38
%
0.17
14
103
8
67
1.21
0.17
1.3
1.5
—
—
—
0
0
19
206
0.91
0.09
5.2
3.7
14.22
9.98
mg/mmol
0.14
11
131
12
134
0.88
0.09
2.0
2.1
—
—
—
0
0
14
149
0.93
0.03
2.0
2.2
—
—
—
0
0
84
831
1.05
0.03
5.8
4.1
5.51
5.83
mmol/l
2.20
79
769
0
5
0.00
0.00
0.0
4.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
2.2
—
—
—
0
0
0
5
0.00
0.00
0.0
4.8
—
—
—
0
0
9
95
0.94
-0.00
1.3
1.7
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_BEHCET and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_BEHCET | 1.717 [1.24, 2.37] | 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.166 |
During the follow-up period (1.1.1998 — 31.12.2019), 98 out of 370 females with M13_BEHCET died.
Males
No dataMortality risk
Mortality risk for people of age
years, who have M13_BEHCET.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.128% | No data |
| 5 | 0.803% | No data |
| 10 | 2.061% | No data |
| 15 | 4.356% | No data |
| 20 | 7.527% | No data |
Relationships between endpoints
↥Index endpoint: M13_BEHCET – Behçet disease
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data